查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
多發性硬化症治療藥的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180685

多發性硬化症治療藥的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)

Multiple Sclerosis Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

全球多發性硬化症治療藥的市場，由於MS的盛行率增加，重大的未滿足需求，有前途的開發平台分子等要素，急速擴大。

本報告提供全球多發性硬化症治療藥市場調查，市場概要，市場分析，各分子、各給藥途徑、各地區的分析，競爭情形，及企業簡介等全面性資訊。

目錄

第1章 序文

  • 報告的說明
    • 報告的目的
    • 目標受眾
    • 主要的產品
  • 市場區隔
  • 調查手法
    • I期 - 2次調查
    • II期 - 1次調查
    • III期 - 專家的審查
    • 前提條件
    • 所採用的方法

第2章 摘要整理

  • 市場概述:全球多發性硬化症治療藥市場
  • 全球多發性硬化症治療藥市場，各分子，2021年
  • 全球多發性硬化症治療藥市場，各給藥途徑，2021年
  • 全球多發性硬化症治療藥市場，各地區，2021年
  • 富有魅力的投資提案，各地區，2021年

第3章 多發性硬化症治療藥市場:競爭分析

  • 主要的多發性硬化症治療藥市場供應商的市場定位
  • 多發性硬化症治療藥市場供應商採用的策略
  • 主要的產業策略
  • 等級分析，2021年對2030年

第4章 多發性硬化症治療藥市場:常量分析和市場動態

  • 簡介
  • 全球多發性硬化症治療藥的市場金額(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析

第5章 多發性硬化症治療藥市場:各分子(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 生技藥品
    • 低分子

第6章 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 口服治療藥
    • 非口服治療藥

第7章 北美的多發性硬化症治療藥市場(2020年～2030年)

  • 市場概要
  • 多發性硬化症治療藥市場:各分子(2020年～2030年)
  • 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)
  • 多發性硬化症治療藥市場:各地區(2020年～2030年)
    • 北美

第8章 英國、歐洲聯盟的多發性硬化症治療藥市場(2020年～2030年)

  • 市場概要
  • 多發性硬化症治療藥市場:各分子(2020年～2030年)
  • 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)
  • 多發性硬化症治療藥市場:各地區(2020年～2030年)
    • 英國、歐洲聯盟

第9章 亞太地區的多發性硬化症治療藥市場(2020年～2030年)

  • 市場概要
  • 多發性硬化症治療藥市場:各分子(2020年～2030年)
  • 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)
  • 多發性硬化症治療藥市場:各地區(2020年～2030年)
    • 亞太地區

第10章 南美的多發性硬化症治療藥市場(2020年～2030年)

  • 市場概要
  • 多發性硬化症治療藥市場:各分子(2020年～2030年)
  • 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)
  • 多發性硬化症治療藥市場:各地區(2020年～2030年)
    • 南美

第11章 中東、非洲的多發性硬化症治療藥市場(2020年～2030年)

  • 市場概要
  • 多發性硬化症治療藥市場:各分子(2020年～2030年)
  • 多發性硬化症治療藥市場:各給藥途徑(2020年～2030年)
  • 多發性硬化症治療藥市場:各地區(2020年～2030年)
    • 中東、非洲

第12章 企業簡介

  • Abbvie, Inc.
  • Acorda Therapeutics
  • Acorda Therapeutics, Inc.
  • Bayer HealthCare
  • Biogen
  • Genzyme(Sanofi)
  • GlaxoSmithKline plc.
  • Merck Serono
  • Novartis International AG
  • Pfizer Inc.
  • Teva Pharmaceutical
Product Code: 137627-08-22

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease in adults and women. The global multiple sclerosis drugs market is rapidly growing due to factors such as growing prevalence of MS, significant unmet needs, and promising pipeline molecules.

The report titled "Multiple Sclerosis Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall multiple sclerosis drugs market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on molecule type (biologics and small molecules), route of administration (oral therapeutic drugs, parenteral therapeutic drugs) and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario, pipeline analysis and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global multiple sclerosis drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global multiple sclerosis drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global multiple sclerosis drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Multiple sclerosis (MS) is an autoimmune disease in which the myelin sheath of nerve cells in the brain and spinal cord are damaged. MS organizations have estimated that 2.3 million people are living with the disease worldwide. There is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. For the purpose of the study market is segmented on the basis of molecule type such as biologics and small molecules. It is observed that, in the base year 2016, biologics was major revenue generating segment. Biologics such as Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri are widely used in the market. However, it is estimated that small molecule segment will show highest growth during forecast period due to the expected launch of various oral formulations of small molecules such as ALKS-8700, OS-440, RPC-1063, ACT-128800 and BAF312.

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system, it is a most common neurological disease of adults age between 20-40, affecting over 450,000 patients in the United States and over 3.5 million patients worldwide. Currently, there is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. It is observed that in the base year 2016, parenteral therapeutic drugs were major revenue generating segment because some major parenteral drugs such as Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, Zinbryta are driving the market growth. However, it is estimated that oral therapeutics drugs will show significant market growth during forecast period due to the expected launch of oral pipeline molecule such as OS-440, MD1003, Cladribine, CS-0777, Gilenya, RPC-1063, RPC-1063 and ACT-128800.

In the base year 2021, North America dominated the multiple sclerosis drugs market and it is estimated to show fastest market growth during forecast period. Some factors such as increasing incidence of MS, technological advances, upsurge in funding by government agencies and private organizations in healthcare system and higher cost of treatment medication are prime factors that fueling the growth of multiple sclerosis drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States and about 2.5 million people around the world have MS; about 200 new cases are diagnosed each week in the United States. MS is an expensive disease to treat; it is studied that direct and indirect health care costs range from US$ 8,528 to US$ 54,244 per patient per year in the United States. Europe is the second largest revenue generating regional market for multiple sclerosis. Existence of higher number of target population is driving the market growth in Europe. The Multiple Sclerosis Foundation estimates that the incidence of MS is higher in colder climates, people of Northern European descent have the highest risk of developing MS, no matter where they live.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Multiple Sclerosis Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Multiple Sclerosis Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Molecule

Biologics

Small Molecules

Route of Administration

Oral Therapeutic Drugs

Parenteral Therapeutic Drugs

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Multiple Sclerosis Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Multiple Sclerosis Drugs market?

Which is the largest regional market for Multiple Sclerosis Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Multiple Sclerosis Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Multiple Sclerosis Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Multiple Sclerosis Drugs Market
  • 2.2. Global Multiple Sclerosis Drugs Market, By Molecule, 2021 (US$ Million)
  • 2.3. Global Multiple Sclerosis Drugs Market, By Route of Administration, 2021 (US$ Million)
  • 2.4. Global Multiple Sclerosis Drugs Market, By Geography, 2021 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2021

3. Multiple Sclerosis Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Multiple Sclerosis Drugs Market Vendors
  • 3.2. Strategies Adopted by Multiple Sclerosis Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Multiple Sclerosis Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Multiple Sclerosis Drugs Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Biologics
    • 5.3.2. Small Molecules

6. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 6.3. Market Segmentation
    • 6.3.1. Oral Therapeutic Drugs
    • 6.3.2. Parenteral Therapeutic Drugs

7. North America Multiple Sclerosis Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
  • 7.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
  • 7.4.Multiple Sclerosis Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 7.4.1.1.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 7.4.1.2.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 7.4.1.3.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

8. UK and European Union Multiple Sclerosis Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
  • 8.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
  • 8.4.Multiple Sclerosis Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.1.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.2.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.3.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.4.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.5.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 8.4.1.6.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

9. Asia Pacific Multiple Sclerosis Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
  • 9.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
  • 9.4.Multiple Sclerosis Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.1.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.2.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.3.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.4.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.5.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 9.4.1.6.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

10. Latin America Multiple Sclerosis Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
  • 10.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
  • 10.4.Multiple Sclerosis Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 10.4.1.1.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 10.4.1.2.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 10.4.1.3.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

11. Middle East and Africa Multiple Sclerosis Drugs Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
  • 11.3. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
  • 11.4.Multiple Sclerosis Drugs Market: By Region, 2020-2030, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 11.4.1.1.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 11.4.1.2.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Multiple Sclerosis Drugs Market: By Molecule, 2020-2030, USD (Million)
        • 11.4.1.3.1. Multiple Sclerosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Abbvie, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Acorda Therapeutics
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Acorda Therapeutics, Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bayer HealthCare
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Biogen
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Genzyme (Sanofi)
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. GlaxoSmithKline plc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Merck Serono
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Novartis International AG
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Pfizer Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Teva Pharmaceutical
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 2 Global Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 3 North America Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 4 North America Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 5 U.S. Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 6 U.S. Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 7 Canada Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 8 Canada Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 9 Rest of North America Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 10 Rest of North America Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 11 UK and European Union Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 12 UK and European Union Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 13 UK Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 14 UK Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 15 Germany Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 16 Germany Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 17 Spain Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 18 Spain Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 19 Italy Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 20 Italy Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 21 France Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 22 France Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 23 Rest of Europe Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 24 Rest of Europe Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 25 Asia Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 26 Asia Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 27 China Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 28 China Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 29 Japan Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 30 Japan Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 31 India Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 32 India Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 33 Australia Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 34 Australia Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 35 South Korea Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 36 South Korea Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 37 Latin America Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 38 Latin America Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 39 Brazil Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 40 Brazil Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 41 Mexico Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 42 Mexico Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 43 Rest of Latin America Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 44 Rest of Latin America Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 45 Middle East and Africa Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 46 Middle East and Africa Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 47 GCC Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 48 GCC Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 49 Africa Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 50 Africa Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Multiple Sclerosis Drugs Market By Molecule, 2020-2030, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Multiple Sclerosis Drugs Market By Route of Administration, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Multiple Sclerosis Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Multiple Sclerosis Drugs Market: Quality Assurance
  • FIG. 5 Global Multiple Sclerosis Drugs Market, By Molecule, 2021
  • FIG. 6 Global Multiple Sclerosis Drugs Market, By Route of Administration, 2021
  • FIG. 7 Global Multiple Sclerosis Drugs Market, By Geography, 2021
  • FIG. 8 Market Geographical Opportunity Matrix - Global Multiple Sclerosis Drugs Market, 2021
  • FIG. 9 Market Positioning of Key Multiple Sclerosis Drugs Market Players, 2021
  • FIG. 10 Global Multiple Sclerosis Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 11 Global Multiple Sclerosis Drugs Market, By Molecule, 2021 Vs 2030, %
  • FIG. 12 Global Multiple Sclerosis Drugs Market, By Route of Administration, 2021 Vs 2030, %
  • FIG. 13 U.S. Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 Canada Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Rest of North America Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 UK Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 Germany Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 Spain Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 Italy Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 France Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 Rest of Europe Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 China Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 Japan Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 India Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Australia Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 South Korea Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Asia Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 Brazil Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 Mexico Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Latin America Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 31 GCC Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 32 Africa Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030
  • FIG. 33 Rest of Middle East and Africa Multiple Sclerosis Drugs Market (US$ Million), 2020 - 2030